<DOC>
	<DOC>NCT02867358</DOC>
	<brief_summary>The purpose of this study is to investigate clinical efficacy of KT07 capsule in alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza.</brief_summary>
	<brief_title>A Clinical Trial of KT07 Capsule in the U.S.A</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>1. Subjects with mild or moderate acute uncomplicated influenza, and oral temperature of 37.339.3℃ (99.1102.8° F); plus at least one respiratory symptoms (nasal congestion, sore throat or cough); and at least one constitutional symptoms (aches and pains, fatigue, headache and chills or sweats). 2. Subjects who have recently been exposed to patients infected with influenza virus with or without rapid influenza diagnostic test (RIDT) confirmed influenza infection (influenza virus A or B infection). 3. Onset of symptoms less than 48 hours before Visit 1 (Screening; study drug administration visit) and receiving no antiviral/antiinfluenza medication. 4. Age 18 to 50 years old. 5. Subjects who are able to understand and are willing to sign the informed consent form (ICF). 6. All female subjects must have a negative urine pregnancy test result . All female subjects and male subjects and their spouse/partner must agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days for female and 90 days for male subjects after study drug discontinuation. 1. Subjects who suffer from severe influenza with oral temperature of more than 39.3℃ (102.8°F) with or without other symptoms. 2. Subjects who have any of following documented conditions: lower respiratory tract infection other than influenza, asthma requiring daily therapy, including acute flare of chronic asthma and bronchial asthma, chronic obstructive pulmonary disease (COPD), acute infectious disease, any other chronic respiratory disease, bacterial infection of respiratory system, such as: suppurative tonsillitis, acute tracheobronchitis, sinusitis, otitis; subjects with history of moderate to severe cardiac, hepatic, renal and hematopoietic disorders, bleeding tendency or hemorrhagic disease,mental and neurological system disease; subjects with hypertension, diabetes, hyperthyroidism and increased intraocular pressure; and subjects with cancer. 3. Subjects with anatomical nasal obstruction or gross anatomical abnormalities. For example, nasal polyps or significant nasal septal deviation. 4. Subjects who have to take other medications for the treatment of influenza or related symptoms, including but not limited to antipyretic and analgesic medicines, antibiotics, and antiviral drugs. 5. Subjects with acute dyspnea, wheezing, moist rales on screening examination. 6. Clinically very excessively obese subjects with BMI≥40. 7. Alcoholism or substance abuse history. 8. Subjects received influenza vaccine within 6 months. 9. Participation in other clinical trial within 1 month. 10. Pregnant or breastfeeding females subjects 11. Allergy or known allergy to components of study medication. 12. Allergy to aspirin or nonsteroid antiinflammatory drugs (NSAIDs), such as ibuprofen. 13. Subjects received antipyretic and/or analgesic medications for conditions other than influenza such as back pain prior to randomization. 14. Administration of immunomodulators, interferon inducers, homeopathic, hormonal other than hormone replacement therapy, antiviral and antibacterial drugs during last 4 weeks before the first dose. 15. Any other associated disease or condition which, in the opinion of the investigator, might restrict or impede participation in the study or affect the study results.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>acute uncomplicated influenza</keyword>
</DOC>